Opinion|Videos|March 24, 2025
Safety Protocols With JAK Inhibitors
Panelists discuss how the Measure Up 1 and 2 studies (Simpson 2022) showed that at 52 weeks, 82.0% to 84.9% of upadacitinib patients achieved EASI-75. Common adverse effects (AEs) included acne, cough, and headache, with 4.5% to 7.2% withdrawal rates.
Advertisement
Episodes in this series
Video content above in prompted by the following:
- Discuss the Measure Up 1 and 2 studies (upadacitinib) (Simpson 2022). Do you see similar results in patients who take upadacitinib in your practice? When do you recommend this treatment?
- At 52 weeks, 82.0% and 79.1% of patients taking 15 mg upadacitinib achieved EASI-75, in Measure Up 1 and 2 respectively.
- At 52 weeks, 84.9% and 84.3% of patients taking 30 mg upadacitinib achieved EASI-75, in Measure Up 1 and 2, respectively.
- The most common AEs were acne, cough, headache, herpes zoster, and creatine kinase elevation
- 4.5% of patients taking 15 mg upadacitinib withdrew due to AEs.
- 7.2% of patients taking 30 mg upadacitinib withdrew due to AEs.
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
Advertisement
Advertisement
Trending on HCPLive
1
2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics
2
Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG
3
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
4
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
5